Angiogenesis II-Safety and feasibility of autologous mesenchymal precursor cells (MPCs) in chronic myocardial ischaemia.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000727640

Enrollment

Registered

2005-11-11

Start date

2006-11-02

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Left ventericular electromechanical mapping and adminsitration of MPCs

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Canadian Cardiologic Society (CCS) Angina Scale class III or IV. Attempted best medical therapy including long acting nitrates, beta-blockers, and calcium channel blockers. Doses of each medication should be increased until haemodynamic consequences (bradycardia or hypotension) or intolerable drug-related side effects. Clinical signs and symptoms of significant ischaemia with reversible myocardial ischaemia on perfusion imaging. Subject must be able to complete a minimum of 3 minutes but no more than 10 minutes of Modified Bruce protocol.

Exclusion criteria

Unprotected left main coronary artery disease >50%. Unstable angina pectoris (labile ECG changes) or a change in anti - anginal medication within the last three weeks. Myocardial infarction (Q wave or non-Q wave) and cerebrovascular events within the last three months. Left ventricular (LV) thrombus. Severe peripheral vascular disease precluding femoral artery access. Aortic stenosis that prohibited catheter access to the LV. De - compensated heart failure and/ or severe LV dysfunction (ejection fraction <30%). Hypertrophic or restrictive cardiomyopathy.

Outcome results